NIH: J&J vaccine works against COVID variants

Tuesday, 29. June 2021 19:03

The United States National Institutes of Health (NIH) said on Tuesday that recent trials showed the COVID-19 vaccine developed by Johnson & Johnson's subsidiary Janssen Pharmaceuticals is efficient against virus variants as well.

"The clinical trial testing the Ad26.COV2.S vaccine, by Janssen/Johnson & Johnson, showed that it protected people in Brazil and South Africa during times when new variants dominate," the NIH stated.

However, the agency stressed that further research will be necessary to determine if the jab is effective against the Delta variant, which was first detected in India and currently makes up for 10% of COVID cases in the US.

Related Links: Johnson & Johnson
Author:
Breaking the News / NP